From the Guidelines
Voquenza is not mentioned in the provided evidence, however, based on the context of the question and the available information, it appears that Voquenza might be related to the treatment or prevention of influenza, but without direct evidence, it is not possible to provide a definitive answer.
Given the information provided in the evidence, the focus is on the prevention and control of influenza in children, with recommendations for chemoprophylaxis and treatment using medications such as oseltamivir, zanamivir, peramivir, and baloxavir marboxil [ 1 ].
- The American Academy of Pediatrics (AAP) considers oseltamivir to be the preferred postexposure chemoprophylaxis for patients with influenza A and/or B [ 1 ].
- Postexposure chemoprophylaxis should only be used when antiviral agents can be initiated within 48 hours of exposure [ 1 ].
- The dosage and duration of these medications vary based on the patient's age, weight, and renal function, as outlined in the provided table [ 1 ].
It is essential to note that the provided evidence does not mention Voquenza, and therefore, it is not possible to provide a recommendation or information on its use based on the available data [ 1 ].
In real-life clinical practice, when dealing with influenza prevention and treatment, healthcare providers should rely on evidence-based guidelines and recommendations from reputable sources, such as the AAP and the Centers for Disease Control and Prevention (CDC), to ensure the best possible outcomes for patients [ 1 ].
From the Research
Definition and Usage of Voquenza
- Voquenza is not a term found in the provided studies, however, a similar term "Vonoprazan" is mentioned in several studies 2, 3, 4.
- Vonoprazan is a potassium-competitive acid blocker used for the treatment of Helicobacter pylori infection, non-erosive reflux disease, and gastric and/or duodenal ulcers.
Studies on Vonoprazan
- A study published in The Annals of Pharmacotherapy found that vonoprazan-based therapy demonstrated greater acid inhibition and similar or higher efficacy than proton-pump inhibitor (PPI)-based therapy in treatment-naïve patients and with clarithromycin-resistant infections 2.
- Another study published in Alimentary Pharmacology & Therapeutics found that on-demand vonoprazan may be a potential alternative to continued daily acid suppression therapy for the relief of episodic heartburn in patients with non-erosive reflux disease 3.
- A systematic review with meta-analysis published in Digestive Diseases and Sciences found that vonoprazan is not significantly better than PPI in treating and preventing gastric and/or duodenal ulcers 4.